NCT05917821Not yet recruiting
New Antigens Against Glioblastoma
Identification of New Antigens Against Glioblastoma
Source: ClinicalTrials.gov · Last updated 24 Jul 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In this study the investigators will select and develop potential therapeutic monoclonal antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to test monoclonal antibodies specificity and target distribution, selection of glioblastoma specific functional monoclonal antibodies, identification of candidate targets.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 15 Jun 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Glioblastoma
- NCT number
- NCT05917821
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Aug 2023 to the primary completion date, 30 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not-availability of informed consent
Who the study is looking for
- age \> 18 years;
- Written informed consent
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.